Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma

Activating point mutations in Anaplastic Lymphoma Kinase (ALK) have positioned ALK as the only mutated oncogene tractable for targeted therapy in neuroblastoma. Cells with these mutations respond to lorlatinib in pre-clinical studies, providing the rationale for a first-in-child Phase 1 trial (NCT03...

Descripción completa

Detalles Bibliográficos
Autores principales: Berko, Esther R., Witek, Gabriela M., Matkar, Smita, Petrova, Zaritza O., Wu, Megan A., Smith, Courtney M., Daniels, Alex, Kalna, Joshua, Kennedy, Annie, Gostuski, Ivan, Casey, Colleen, Krytska, Kateryna, Gerelus, Mark, Pavlick, Dean, Ghazarian, Susan, Park, Julie R., Marachelian, Araz, Maris, John M., Goldsmith, Kelly C., Radhakrishnan, Ravi, Lemmon, Mark A., Mossé, Yaël P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163008/
https://www.ncbi.nlm.nih.gov/pubmed/37147298
http://dx.doi.org/10.1038/s41467-023-38195-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163008/
https://www.ncbi.nlm.nih.gov/pubmed/37147298
http://dx.doi.org/10.1038/s41467-023-38195-0

Ejemplares similares